clarithromycin has been researched along with tobramycin in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Esteban, J; Fernández-Martínez, AI; Fernández-Roblas, R; Gadea, I; García-Almeida, D; Martín-de-Hijas, NZ | 1 |
| Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ashenden, S; Bender, A; Cokol, M; Karakoc, I; Kuru, N; Mason, DJ; Meral, S; Stott, I; Weinstein, ZB | 1 |
| Muszynski, MJ; Rajyaguru, JM | 1 |
| Bergmann, JS; Boulet, B; Brown, BA; Fahle, GA; Plaunt, M; Wallace, RJ; Wanger, A; Witebsky, FG; Woods, GL | 1 |
| Ishii, Y; Kobayashi, T; Matsumoto, T; Miyazaki, S; Tateda, K; Yamaguchi, K | 1 |
| Daines, BS; Sandoval, HP; Solomon, KD; Steed, LL; Vroman, DT | 1 |
| Lee, SB; Mohan, SK; Oliver, KM; Slomovic, AR; Strube, YN | 1 |
| Devleeschouwer, MJ; Traore, H; Tré-Hardy, M; Vanderbist, F | 1 |
| Devleeschouwer, MJ; El Manssouri, N; Macé, C; Traore, H; Tré-Hardy, M; Vanderbist, F | 1 |
| Devleeschouwer, MJ; El Manssouri, N; Traore, H; Tré-Hardy, M; Vanderbist, F; Vaneechoutte, M | 1 |
| Fauville-Dufaux, M; Stoffels, K; Traore, H; Vanderbist, F | 1 |
| Biswas, A; Cadwgan, A; Halpern, J; Tan, BB | 1 |
| Bricaire, F; Caumes, E; Monsel, G; Roujeau, JC; Schneider, P; Veziris, N | 1 |
| Amighi, K; Pilcer, G; Rosière, R; Sebti, T; Traina, K; Vanderbist, F | 1 |
| Amighi, K; De Bueger, V; Pilcer, G; Sebti, T; Traina, K; Traore, H; Vanderbist, F | 1 |
| Gui, J; Hong, CY; Li, JL; Liang, J; Wang, F | 1 |
| Bastin, R; Cahay, B; Charif, M; Duysens, G; Elmoualij, B; Heinen, E; Jolois, O; Quatresooz, P; Streel, B; Thellin, O; Zorzi, W | 1 |
| Gu, L; Li, R; Liu, Y; Qu, J; Wang, P; Wei, M; Yang, C | 1 |
| Astudillo, A; Chan, HK; Chang, YK; Parumasivam, T; Sugianto, TD; Sun, S; Tang, P; Wang, S; Ye, T | 1 |
| Afifi, A; De Lord, D; Rasool, S | 1 |
| Arslan, N; Esen, N; Özkarataş, MH; Özkütük, AA | 1 |
1 review(s) available for clarithromycin and tobramycin
| Article | Year |
|---|---|
Rapid diagnosis and treatment of mycobacterial keratitis after laser in situ keratomileusis.
Topics: Amikacin; Bacteriological Techniques; Ciprofloxacin; Clarithromycin; Corneal Ulcer; Diagnostic Techniques, Ophthalmological; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Indicators and Reagents; Keratomileusis, Laser In Situ; Middle Aged; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Myopia; Postoperative Complications; Staining and Labeling; Tobramycin | 2003 |
29 other study(ies) available for clarithromycin and tobramycin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Pigmentation; Species Specificity; Tigecycline | 2008 |
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
Topics: Anti-Bacterial Agents; Drug Interactions; Molecular Structure | 2017 |
Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds.
Topics: 1-Naphthylamine; Anti-Infective Agents; Azithromycin; Bacterial Outer Membrane Proteins; Burkholderia cepacia; Cations; Ceftazidime; Cell Membrane Permeability; Ciprofloxacin; Clarithromycin; Fleroxacin; Fluorescent Dyes; Fluoroquinolones; Gentamicins; Magnesium; Microbial Sensitivity Tests; Microscopy, Electron; Novobiocin; Oxolinic Acid; Polysaccharides, Bacterial; Tobramycin | 1997 |
Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; Ciprofloxacin; Clarithromycin; Culture Media; Doxycycline; Humans; Imipenem; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Sulfamethoxazole; Tobramycin | 1999 |
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Proteins; Ceftazidime; Cephalosporins; Clarithromycin; Clindamycin; Erythromycin; In Vitro Techniques; Josamycin; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Oleandomycin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Time Factors; Tobramycin | 2000 |
Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery.
Topics: Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Postoperative Complications; Quinolines; Surgical Flaps; Tobramycin | 2005 |
In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Polymyxin B; Pseudomonas aeruginosa; Tobramycin | 2008 |
Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Topics: Anti-Bacterial Agents; Biofilms; Burkholderia cepacia; Clarithromycin; Cystic Fibrosis; Drug Combinations; Drug Synergism; Humans; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Staphylococcus aureus; Time Factors; Tobramycin | 2009 |
Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Colony Count, Microbial; Cystic Fibrosis; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Genotype; Humans; Models, Biological; Phenotype; Pseudomonas aeruginosa; Sputum; Time Factors; Tobramycin; Treatment Outcome | 2009 |
The effect of combined tobramycin-clarithromycin on Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tobramycin | 2009 |
Disseminated cutaneous Mycobacterium chelonae infection in an immunocompetent host.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Skin Diseases, Bacterial; Tobramycin; Treatment Outcome | 2010 |
Successful treatment of nodular lymphangitis due to Mycobacterium chelonae in two immunosuppressed patients.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Injections, Intravenous; Lymphangitis; Male; Middle Aged; Minocycline; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Tigecycline; Tobramycin; Treatment Outcome | 2011 |
New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Desiccation; Drug Delivery Systems; Humans; Lung; Lung Diseases; Nanoparticles; Powders; Respiratory Tract Infections; Solubility; Tobramycin | 2013 |
Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Crystallization; Cystic Fibrosis; Drug Combinations; Drug Compounding; Drug Synergism; Dry Powder Inhalers; Lung; Lung Diseases; Microscopy, Electron, Scanning; Particle Size; Powders; Tissue Distribution; Tobramycin; X-Ray Diffraction | 2013 |
[Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
Topics: Acetamides; Amikacin; Anti-Bacterial Agents; Cefoxitin; Clarithromycin; Culture Media; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Oxazolidinones; Sensitivity and Specificity; Tobramycin | 2013 |
In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Cell Survival; Clarithromycin; Culture Media; Drug Synergism; Humans; Microbial Viability; Pseudomonas aeruginosa; Tobramycin | 2015 |
Identification and antimicrobial susceptibility of clinical Nocardia species in a tertiary hospital in China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nocardia; Nocardia Infections; Population Surveillance; Tertiary Care Centers; Tobramycin; Young Adult | 2017 |
Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Desiccation; Drug Combinations; Drug Compounding; Drug Liberation; Liposomes; Pseudomonas aeruginosa; Tobramycin | 2018 |
Case of atypical cutaneous
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Imipenem; Immunocompromised Host; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Skin Diseases, Bacterial; Tobramycin; Treatment Outcome | 2019 |
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; Ciprofloxacin; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tobramycin | 2023 |